Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

Canopy Growth Is Surging and Analysts Still Think It Can Gain 40% from Here

Canopy Growth (CGC) shares have been in a sharp uptrend this week following reports President Donald Trump will reclassify cannabis as a “Schedule III” drug within the next few days. 

Additionally, the president is also considering announcing a Medicare pilot program that would let some seniors access cannabis products at a subsidized rate. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.